iSPOT-D: International Study to Predict Optimized Treatment - in Depression
Official Title: International Study to Predict Optimized Treatment - in Depression
Purpose of the Study: The goal of this study is to identify psychological, physical and genetic markers that may help predict response to antidepressants treatments in patients with major depressive disorder (MDD). This study will assess the impact of ‘personalized medicine’ in MDD.
Description: This is an open-label, randomized study to identify genetic markers, brain function, brain structure, and psychological and cognitive indicators that might predict response to antidepressants treatments Escitalopram, Sertraline or Venlafaxine XR. Participants must take part in 2 days of assessments and complete 8 Web-based follow up questionnaires over a 12-month period. The assessments/procedures include: baseline clinical work-up, blood collection for genetic analyses, cognitive testing and electrical brain functioning (EEG/ERP). Structural and functional data MRI data will be collected in 10 percent of participants.
Eligibility Criteria: Adults 18 – 65 years who meet the DSM IV criteria for MDD, HAM-D17 score of 16 or more
Principal Investigator: Subhdeep Virk, MD
Funding/Study Support: BRC Operations Pty. Ltd.